• Home
  •  / STERO Biotechs

STERO Biotechs

    OverviewSuggest Edit

    STERO Biotechs is a biotechnology company engaged in the research and development of cannabidiol (CBD)-based treatment solutions. It develops ST-101, a product that is is targeted for steroid sparing in multiple indications. STERO's main focus is aimed at inflammatory bowel diseases (IBD) and steroid-dependent Crohn’s disease.

    TypePrivate
    Founded2017
    HQBnei Brak, ILMap
    Websitesterobiotechs.com

    Recent NewsAll News

    Latest Updates

    Employees (est.) (Jan 2021)1
    Cybersecurity ratingBMore

    Key People/Management at STERO Biotechs

    David Bassa

    David Bassa

    CEO
    Ofer Alshech

    Ofer Alshech

    CFO
    Guy Defrin

    Guy Defrin

    COO
    Moshe Yeshurun

    Moshe Yeshurun

    CTO
    Sari Prutchi Sagiv

    Sari Prutchi Sagiv

    CSO
    Naftali Timna

    Naftali Timna

    IBD Medical Director
    Show more

    STERO Biotechs Office Locations

    STERO Biotechs has an office in Bnei Brak
    Bnei Brak, IL (HQ)
    Barukh Hirsch St 14, Bnei Brak
    Show all (1)

    STERO Biotechs Financials and Metrics

    Summary Metrics

    Founding Date

    		2017

    STERO Biotechs investors

    		BioSeedXL, MOR Research Applications
    Show all financial metrics

    STERO Biotechs Operating Metrics

    Aug, 2018Mar, 2020

    Patents

    		1

    Phase II Patients Enrolled

    		43

    Phase II Trials Products

    		2
    Show all operating metrics

    STERO Biotechs Cybersecurity Score

    Cybersecurity ratingPremium dataset

    B

    89/100

    Learn more about our premium products
    SecurityScorecard logo

    STERO Biotechs Online and Social Media Presence

    STERO Biotechs's Trends

    Embed Graph

    STERO Biotechs News and Updates

    April 13, 2020

    Kalytera and Stero Biotechs Will Not Proceed with Acquisition

    SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has announced that it will not proceed with the previously announced acquisition of Stero Biotechs, Ltd. (“Stero”), and that Stero and Kalytera have termi…
    March 18, 2020

    Kalytera Provides Additional Detail Regarding Terms of Stero Biotechs, Ltd. Acquisition

    SAN FRANCISCO and TEL AVIV, Israel, March 18, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided additional details regarding the terms of its planned acquisition of Stero Biotechs, Ltd. (“Stero”). Stero is a privat…
    March 05, 2020

    Kalytera to Acquire Stero Biotechs, Ltd.

    Acquisition Will Bring Kalytera Multiple Additional CBD Pharmaceutical Programs
    September 16, 2019

    CBD as an Alternative Steroid: Is Cannabidiol a Viable Option to Use?

    July 23, 2019

    Stero Biotechs to Commence Phase 2a Clinical Trial of Cannabidiol-Based Formulation for Patients With Crohn's Disease

    August 29, 2018

    STERO Biotechs Secures Patent of CBD as Steroid Sparing Treatment, Breakthrough Will Potentially Allow Significant Dosage Reduction

     STERO Biotechs Frequently Asked Questions

    • When was STERO Biotechs founded?

      STERO Biotechs was founded in 2017.

    • Who are STERO Biotechs key executives?

      STERO Biotechs's key executives are David Bassa, Ofer Alshech and Guy Defrin.

    • How many employees does STERO Biotechs have?

      STERO Biotechs has 1 employees.

    • Who are STERO Biotechs competitors?

      Competitors of STERO Biotechs include CBGenius, Kaleidoscope Labs and CannaSoul Analytics.

    • Where is STERO Biotechs headquarters?

      STERO Biotechs headquarters is located at Barukh Hirsch St 14, Bnei Brak, Bnei Brak.

    • Where are STERO Biotechs offices?

      STERO Biotechs has an office in Bnei Brak.

    • How many offices does STERO Biotechs have?

      STERO Biotechs has 1 office.